Search Medical Condition
Please enter condition
Please choose location

Moskow, Russian Federation Clinical Trials

A listing of Moskow, Russian Federation clinical trials actively recruiting patients volunteers.

RESULTS

Found (228) clinical trials

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

The primary objective is to compare the efficacy of SM-13496 (20-60 or 80-120 mg/day) monotherapy with that of placebo in patients with depressive symptoms associated with bipolar I disorder by assessing the change from baseline in the MADRS total score at Week 6.

Phase

0.0 miles

Learn More »

A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

The study objective is to evaluate the long-term efficacy and safety of SM-13496 (20-120 mg/day) in patients with bipolar I disorder.

Phase

0.0 miles

Learn More »

Tedizolid Phosphate (TR-701 FA) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)

The primary objective is to determine the noninferiority (NI) in all-cause mortality (ACM) within 28 days after randomization of IV tedizolid phosphate compared with IV linezolid in the Intent to Treat (ITT) Analysis Set in ventilated participants with presumed gram-positive HABP or gram-positive VABP, collectively defined as ventilated nosocomial pneumonia ...

Phase

0.0 miles

Learn More »

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients Not on Dialysis in Comparison to Darbepoetin Alfa

This study will consist of three study periods as follows: - Screening Period: from 2 up to 6 weeks - Treatment Period: 104 weeks - Follow-up Period: 4 weeks

Phase

0.0 miles

Learn More »

Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)

This is a phase 3, multicenter, prospective, randomized study of intravenous (IV) ceftolozane/tazobactam vs. IV meropenem in the treatment of adult participants with either ventilator-associated bacterial pneumonia (VABP) or ventilated hospital-acquired bacterial pneumonia (HABP).

Phase

0.0 miles

Learn More »

Clinical Trial of Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children

The study shall enroll outpatient subjects of both sexes aged 3-12 years with clinical manifestations of influenza/Acute Respiratory Viral Infections (ARVI), including fever of at least 38.0 С, who sought medical aid within the first day of the illness onset. Тhe doctor shall collect medical history information, perform an objective ...

Phase

0.0 miles

Learn More »

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

This is a Phase Ib, open-label, multicentre study of AZD9291 administered orally in combination with novel therapeutics (AZD6094 or selumetinib (AZD6244, ARRY142886)) to patients with EGFRm+ advanced NSCLC. The study has been designed to allow an investigation of the optimal combination dose and schedule whilst ensuring the safety of patients ...

Phase

0.0 miles

Learn More »

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

This open-label extension of the JIGSAW studies (WA28117 [NCT01904279] and WA28118 [NCT01904292]) is designed to evaluate the long-term safety and efficacy of subcutaneous (SC) tocilizumab treatment in participants with polyarticular-course and systemic juvenile idiopathic arthritis (pJIA and sJIA). Participants from the 2 JIGSAW studies will continue to receive 162 milligrams ...

Phase

0.0 miles

Learn More »

A Clinical Study in Subjects With Huntington's Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod

The primary objective of this study is to assess the efficacy of laquinimod 0.5, 1.0, and 1.5 mg qd in patients with HD after 12 months of treatment using the UHDRS-TMS.

Phase

0.0 miles

Learn More »

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is ...

Phase

0.0 miles

Learn More »